Agios Pharmaceuticals AGIO Total Liabilities & Equity
Total Liabilities & Equity at other companies
Other financials
Where this comes from
Reported directly by Agios Pharmaceuticals in its filing.
Tagged under the XBRL concept us-gaap:LiabilitiesAndStockholdersEquity.
The official record: Agios Pharmaceuticals’s 10-Q, filed April 29, 2026, on SEC EDGAR. View the filing →
Ask your AI about Agios Pharmaceuticals's total liabilities & equity.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Agios Pharmaceuticals's total liabilities & equity?
- Agios Pharmaceuticals (AGIO) reported total liabilities & equity of $1.18B in Q1 2026.
- How has Agios Pharmaceuticals's total liabilities & equity changed year-over-year?
- Agios Pharmaceuticals's total liabilities & equity decreased by 23.8% year-over-year, from $1.56B to $1.18B.
- What is the long-term trend for Agios Pharmaceuticals's total liabilities & equity?
- Over 5 years (2020 to 2025), Agios Pharmaceuticals's total liabilities & equity has grown at a 8.7% compound annual growth rate (CAGR), from $852.95M to $1.3B.
- What does total liabilities & equity mean?
- Total assets = total liabilities + total equity. This must always balance — a fundamental accounting identity.